Eli Lilly and Company has announced the launch of Ramiven (abemaciclib), following approval from the DCGI (India) + endocrine therapy for adjuvant treatment in HR-positive, HER2 negative early breast cancer
Eli Lilly and Company has announced the launch of the additional indication for Ramiven (abemaciclib), following approval from the Drugs Controller General of India (DCGI) in combination with endocrine therapy for adjuvant treatment in adult patients with Hormone Receptor (HR)-positive, human epidermal growth factor receptor 2(HER2) negative, node-positive Early Breast Cancer (EBC) at high risk of recurrence
CDK 4/6 inhibitors are a class of medicines used to treat certain types of metastatic breast cancers. In India, over 50,000 patients are diagnosed with HR+/HER2- early breast cancer (EBC) every year. Close to 30 per cent of EBC patients with high-risk clinical or pathological features experience recurrence or metastasis despite receiving standard therapy.
Ramiven is already approved for the treatment of certain types of HR+ HER2- advanced or metastatic breast cancer.
Related news and insights
Regeneron Pharmaceuticals, Inc. and Sanofi announced that the European Commission (EC) expanded the marketing authorization for Dupixent (dupilumab) in the European Union (EU) to treat eosinophilic esophagitis (EoE) in adults and adolescents 12 years and older, weighing at least 40 kg, who are inadequately controlled by, are intolerant to, or who are not candidates for conventional medicinal therapy
Sandoz, a global leader in off-patent (generic and biosimilar) medicines, announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA), has adopted a positive opinion for marketing authorization for a citrate-free high concentration formulation (HCF) of its biosimilar Hyrimoz (adalimumab)
Roche announced that the Phase III IMbrave050 study met its primary endpoint of recurrence-free survival (RFS) at the prespecified interim analysis.